Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis

Detalles Bibliográficos
Autores principales: Kant, Sam, Azar, Antoine, Geetha, Duvuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Nephrology. Published by Elsevier Inc. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607746/
https://www.ncbi.nlm.nih.gov/pubmed/34822874
http://dx.doi.org/10.1016/j.kint.2021.11.012
_version_ 1784602622910529536
author Kant, Sam
Azar, Antoine
Geetha, Duvuru
author_facet Kant, Sam
Azar, Antoine
Geetha, Duvuru
author_sort Kant, Sam
collection PubMed
description
format Online
Article
Text
id pubmed-8607746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Society of Nephrology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-86077462021-11-22 Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis Kant, Sam Azar, Antoine Geetha, Duvuru Kidney Int Letter to the Editor International Society of Nephrology. Published by Elsevier Inc. 2022-02 2021-11-22 /pmc/articles/PMC8607746/ /pubmed/34822874 http://dx.doi.org/10.1016/j.kint.2021.11.012 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Kant, Sam
Azar, Antoine
Geetha, Duvuru
Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title_full Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title_fullStr Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title_full_unstemmed Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title_short Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
title_sort antibody response to covid-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607746/
https://www.ncbi.nlm.nih.gov/pubmed/34822874
http://dx.doi.org/10.1016/j.kint.2021.11.012
work_keys_str_mv AT kantsam antibodyresponsetocovid19boostervaccineinrituximabtreatedpatientswithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT azarantoine antibodyresponsetocovid19boostervaccineinrituximabtreatedpatientswithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT geethaduvuru antibodyresponsetocovid19boostervaccineinrituximabtreatedpatientswithantineutrophilcytoplasmicantibodyassociatedvasculitis

Ejemplares similares